What Is a Peptide-Drug Conjugate (PDC)?

1. Introduction: The Evolution After Multi-Agonists

Peptide research has achieved transformative progress in recent decades, particularly in the field of metabolic diseases. The development of GLP-1 receptor agonists (GLP-1R) marked a turning point. This was followed by the next generation: dual agonists, which simultaneously address the GLP-1R and the GIP receptor (GIPR), demonstrating superior efficacy by activating complementary signaling pathways. With the preclinical investigation of molecules such as the Triple-Agonist Peptide, which simultaneously activates GLP-1R, GIPR, and the GCG Receptor (GCGR), the complexity at the peptide level seemed to reach a plateau.

However, scientific innovation continues relentlessly. The next evolutionary stage in the development of highly specific drug molecules is already emerging: Peptide-Drug Conjugates (PDCs). While multi-agonists perfect the art of simultaneous signal transduction via multiple membrane-bound receptors, PDCs go a crucial step further. They utilize the exquisite targeting precision of peptides not just for pure signaling, but as a precise navigation system to transport a highly potent "molecular cargo" (drug payload) directly into specific target cells. This article illuminates the scientific foundations, structure, potential, and challenges of this fascinating class of molecules for researchers in the preclinical environment.

2. Definition: PDC vs. Classical Peptides – A Paradigm Shift

To fully grasp the concept of PDCs, a clear distinction from classical therapeutic peptides is necessary.

Classical peptides (e.g., mono-, dual-, triple-agonists) are short amino acid chains that mimic endogenous hormones or ligands in their function. Their primary role is to interact with extracellular receptors on the cell surface. By binding to these receptors, they initiate intracellular signaling cascades (e.g., cAMP production) that elicit a physiological response. Their effect is thus limited to signal transduction.

Peptide-Drug Conjugates (PDCs), on the other hand, are hybrid constructs that exhibit functional duality. They consist of two covalently linked main components: 1. A peptide carrier, responsible for targeted navigation and binding to a specific cell surface receptor. 2. A drug payload, which can be a highly potent small molecule, a cytotoxin, or another active substance that typically exerts its effect intracellularly.

The crucial difference lies in the paradigm: a classical peptide is the active substance. In a PDC, the peptide carries the actual active substance to the target. The peptide acts as a "homing device," and the entire construct functions as a sophisticated delivery system designed to minimize systemic exposure and associated off-target effects of the payload.

3. Molecular Structure: Carrier, Payload, and Linker

The functionality and efficacy of a PDC critically depend on the design and synergistic interaction of its three core components.

The Peptide Carrier: Precision as a Guiding Principle

The peptide carrier is the decisive element for the specificity of the PDC. Its selection is based on high affinity and selectivity for a receptor that is overexpressed on target cells, while being present only in small amounts on healthy tissues. This is the basis for targeted transport. Examples of target receptors in current research include:

• Somatostatin receptors (SSTRs), which are overexpressed in neuroendocrine tumors.
• GLP-1 receptors (GLP-1R), which are expressed not only in the pancreas but also in the heart, brain, and adipose tissue, and can thus serve as targets for organ-specific drug delivery.
• Prostate-specific membrane antigen (PSMA) for the treatment of prostate carcinoma.

For use in research, these peptides often need to be chemically modified to increase their stability against proteases in the bloodstream and prolong their pharmacokinetic half-life. This can be achieved by incorporating non-proteinogenic amino acids, cyclization, or conjugation with polymers or fatty acids.

The Drug Payload: The "Molecular Cargo"

The payload is the pharmacologically active part of the PDC that exerts its effect after internalization into the target cell. The range of potential payloads is enormous and an active field of research:

• Cytotoxic agents: Highly potent chemotherapeutic agents (e.g., auristatins, maytansinoids) that would be too toxic for systemic administration.
• Small-molecule inhibitors: Targeted inhibitors of kinases or other enzymes whose effect is to be restricted to the target cell.
• Agonists/antagonists for intracellular receptors: Active substances that, for example, modulate nuclear receptors.
• Radioisotopes: For therapeutic (radioligand therapy) or diagnostic (imaging) purposes.

The choice of payload is determined by the research goal and the need to overcome cellular permeability barriers, which the payload alone often cannot do.

The Linker: The Critical Connection

The linker is far more than just a spacer. It covalently connects the carrier to the payload, and its chemistry largely determines the stability of the PDC in the bloodstream and the release profile of the active substance in the target cell. Two main classes are distinguished:

• Cleavable linkers: These are designed to be cleaved under the specific conditions of the intracellular compartment (e.g., in the endosome or lysosome). Triggers can be a low pH (acid-labile linkers), an altered redox potential (disulfide linkers), or the presence of specific enzymes such as cathepsins (peptide-based linkers). This allows for controlled, site-specific release of the active payload.
• Non-cleavable linkers: In this approach, the payload remains covalently bound to the carrier (or to a single amino acid) after the peptide has been proteolytically degraded in the lysosome. The resulting drug-linker-amino acid construct must itself be biologically active. This approach often offers higher plasma stability but places higher demands on the design of the payload.

4. Application Example "GLP5": Synergy at a New Level

To illustrate the potential of PDCs, let's consider the hypothetical research construct GLP5. This is a PDC that combines the principles of multi-agonists with targeted drug transport.

• Peptide Carrier: A modified peptide backbone that acts as an agonist for both GLP-1R and GIPR. This dual targeting already ensures high specificity for cells in the metabolic system (e.g., pancreas, adipose tissue, hypothalamus).
• Payload: A potent, small-molecule agonist that simultaneously activates the peroxisome proliferator-activated receptors PPAR-α, -γ, and -δ. These nuclear receptors are central regulators of lipid and glucose metabolism.
• Mechanism: After systemic administration, the GLP-1R/GIPR-agonistic part of the GLP5 molecule binds to the corresponding receptors on the target cell. This initiates the "classical" signal transduction (e.g., increased cAMP) and simultaneously triggers the internalization of the entire conjugate via endocytosis. In the acidic environment of the lysosome, the cleavable linker is hydrolyzed, and the PPAR agonist is released. This diffuses from the lysosome into the cell nucleus, where it binds to the PPARs and modulates the transcription of target genes.

The resulting synergy is remarkable: in one and the same cell, membrane-bound signaling pathways (via GLP-1/GIP) and nuclear signaling pathways (via PPARs) are simultaneously activated. Such targeted, intracellular co-activation could not be achieved with comparable precision by separate administration of the individual components (Knerr et al., Nature 2024).

5. Advantages for Preclinical Research

The PDC technology offers a number of significant advantages that make it a promising tool for basic and translational research:

• Increased Tissue Specificity: By targeted accumulation in the target tissue, researchers can investigate the effects of an active substance while minimizing systemic influences.
• Reduced Off-Target Risk: Highly potent or cytotoxic substances can be precisely delivered to their site of action, which could significantly expand the therapeutic window in potential later applications.
• Improved Pharmacokinetics (PK): The peptide backbone can be modified to extend the half-life of the entire conjugate. This allows for the investigation of long-term effects with reduced application frequency.
• Intracellular Multi-Pathway Activation: PDCs enable the study of synergistic effects resulting from the simultaneous modulation of surface receptors and intracellular targets.
• Overcoming Permeability Barriers: PDCs can serve as a "Trojan horse" to deliver membrane-impermeable payloads into the cytosol or nucleus.

6. Limitations and Open Research Questions

Despite the enormous potential, scientific and technical challenges exist that are the subject of intensive research:

• Chemical Complexity: The synthesis and characterization of a homogeneous PDC, in which the carrier, linker, and payload are in a defined stoichiometric ratio, is challenging.
• Linker Stability: The balance between sufficient stability in plasma and efficient cleavage in the target cell is a critical optimization parameter. Premature release of the payload can lead to systemic toxicity.
• Immunogenicity: As with all biologics, there is a risk of an immune response against the peptide or the entire conjugate.
• Resistance Mechanisms: Target cells can develop resistance to PDCs by downregulating the target receptor or by modifying the intracellular release machinery.
• Manufacturing and Scalability: Multi-step synthesis is costly and time-consuming, which poses a hurdle, especially for later clinical translation.

7. Outlook: The PDC Pipeline in Research

PDCs are far more than just a niche concept. While oncology is the most advanced field for PDCs, the technology opens new horizons in numerous other research areas. The preclinical pipeline is rich in innovative approaches:

• Neurodegenerative Diseases: PDCs whose carriers can cross the blood-brain barrier to deliver neuroprotective or anti-inflammatory payloads directly into the CNS.
• Immunology: Targeted delivery of immunomodulatory substances to specific subpopulations of immune cells.
• Diagnostics: Conjugation of peptides with imaging probes (e.g., fluorophores, PET tracers) for highly sensitive visualization of receptor expressions in vivo.

Future innovations, such as the development of novel linker technologies with orthogonal cleavage mechanisms or the use of structurally defined peptide scaffolds, will further enhance the precision and versatility of the PDC platform (Liskiewicz et al., Nature 2026, PMID 42056522). PDCs thus represent a fundamental advance that has the potential to push the boundaries of molecular research.

---

Important Note for Researchers (Research Use Only)

The substances described in this article and available in our shop, including the Triple-Agonist Peptide discussed here and hypothetical constructs like GLP5, are intended exclusively for Research Use Only (RUO) in a controlled laboratory environment.

These products are not approved or intended for human or veterinary use. The information presented here is purely for scientific education and does not constitute medical advice, application recommendations, or a health claim.